SCHEMBL5569980

SCHEMBL5569980

CNC(=O)c1cn2c(C)c(C)nc2c(O)c1CC[C@@H](O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
TP53 P04637 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 3/20 0.34
POLB P06746 1/20 0.34
CXCR2 P25025 2/20 0.34
CYP3A4 P08684 4/20 0.33
CYP2C9 P11712 4/20 0.33
CYP2D6 P10635 2/20 0.33
ALDH1A1 P00352 3/20 0.33
KLKB1 P03952 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569978 1.00 LMNA (0.38) LMNATP53MAPTNPC1RAB9A
SCHEMBL4977670 0.90 P2RX3 (0.36) LMNATP53MAPTNPC1RAB9A
SCHEMBL5449403 0.88 MCHR1 (0.41) MAPTNPC1RAB9AKDM4EPOLB
SCHEMBL5327517 0.88 MCHR1 (0.41) MAPTNPC1RAB9AKDM4EPOLB
SCHEMBL5327514 0.88 MCHR1 (0.41) MAPTNPC1RAB9AKDM4EPOLB
SCHEMBL4977432 0.86 PRKDC (0.34) LMNATP53MAPTNPC1RAB9A
SCHEMBL5451120 0.86 PRKDC (0.34) LMNATP53MAPTNPC1RAB9A
SCHEMBL5566372 0.86 PRKDC (0.34) LMNATP53MAPTNPC1RAB9A
SCHEMBL5558310 0.85 MAPT (0.39) LMNATP53MAPTNPC1RAB9A
SCHEMBL5329027 0.83 KMT2A (0.37) LMNAMAPTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR LMNA 4864/4885TP53 3829/4885MAPT 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.